CPX-351 (liposomal daunorubicin + cytarabine)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-02-04 — Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms: cross-connection with cpx-351-secondary-myeloid-neoplasms-pediatric: Pediatric/young adult trial extends the adult CPX-351 evidence base into a younger population with secondary myeloid neoplasms. (novelty: 3)
- 2026-04-24 — Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms: Phase I/II trial (trial-early): CPX-351 being evaluated in combination with ruxolitinib in accelerated or blast phase MPN — first formal trial combining liposomal daunorubicin/cytarabine with a JAK inhibitor in this high-risk population. (novelty: 3)
Open questions
Related
Contributing findings
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
20-may-2026
novelty 2
per-area 2
strengthens
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
24-apr-2026
novelty 3
per-area 3
introduces